Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Nash

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Heart (British Cardiac Society)|April 24, 2016
Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in TanzaniaJustin R Kingery, Yona Alfred, Luke R Smart, et al.
Breast Cancer Research and Treatment|June 13, 2023
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real worldMegan Kruse, Emily Nash Smyth, Lee Bowman, et al.
Drugs - Real World Outcomes|September 29, 2023
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical PracticeAlistair Ring, Meghan Karuturi, Emily Nash Smyth, et al.
Dermatology and Therapy|September 2, 2015
A Qualitative Comparison of Symptoms and Impact of Varying Stages of Basal Cell CarcinomaAnna W Steenrod, Emily Nash Smyth, Elizabeth N Bush, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|August 7, 2020
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United StatesRavi K Goyal, Gebra Cuyun Carter, Saurabh P Nagar, et al.
Current Medical Research and Opinion|May 10, 2022
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community settingGregory L Price, Lavanya Sudharshan, Paula Ryan, et al.
Clinical Breast Cancer|March 8, 2021
Development of a Prognostic Factor Index Among Women With HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer in a Community Oncology SettingGregory A Vidal, Gebra Cuyun Carter, Adrienne M Gilligan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 5, 2026
Genotoxic pks + E. coli is strongly associated with ileocolonic neoplasia in adults with Cystic FibrosisJosie van Dorst, Nicole Taylor, B L D Uthpala Pushpakumara, et al.
Current Medical Research and Opinion|May 10, 2021
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancerGebra Cuyun Carter, Kristin M Sheffield, Anala Gossai, et al.
Environmental Monitoring and Assessment|July 30, 2025
Lead exposure in homes as modifying factors of blood lead levels among young children in Bihar, IndiaEmily Nash, Yi Lu, Stephan Bose-O'Reilly, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Heart (British Cardiac Society)|April 24, 2016
Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in TanzaniaJustin R Kingery, Yona Alfred, Luke R Smart, et al.
Breast Cancer Research and Treatment|June 13, 2023
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real worldMegan Kruse, Emily Nash Smyth, Lee Bowman, et al.
Drugs - Real World Outcomes|September 29, 2023
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical PracticeAlistair Ring, Meghan Karuturi, Emily Nash Smyth, et al.
Dermatology and Therapy|September 2, 2015
A Qualitative Comparison of Symptoms and Impact of Varying Stages of Basal Cell CarcinomaAnna W Steenrod, Emily Nash Smyth, Elizabeth N Bush, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|August 7, 2020
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United StatesRavi K Goyal, Gebra Cuyun Carter, Saurabh P Nagar, et al.
Current Medical Research and Opinion|May 10, 2022
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community settingGregory L Price, Lavanya Sudharshan, Paula Ryan, et al.
Clinical Breast Cancer|March 8, 2021
Development of a Prognostic Factor Index Among Women With HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer in a Community Oncology SettingGregory A Vidal, Gebra Cuyun Carter, Adrienne M Gilligan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 5, 2026
Genotoxic pks + E. coli is strongly associated with ileocolonic neoplasia in adults with Cystic FibrosisJosie van Dorst, Nicole Taylor, B L D Uthpala Pushpakumara, et al.
Current Medical Research and Opinion|May 10, 2021
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancerGebra Cuyun Carter, Kristin M Sheffield, Anala Gossai, et al.
Environmental Monitoring and Assessment|July 30, 2025
Lead exposure in homes as modifying factors of blood lead levels among young children in Bihar, IndiaEmily Nash, Yi Lu, Stephan Bose-O'Reilly, et al.
Pageof 6